Ozempic
Overview
- Drug Brand Name: Ozempic
- Active moiety or active ingredient: semaglutide
- Application Number: NDA209637
- Ozempic NDC 11s in the Cost Review Study Process
Ozempic Cost Review Study Process
Ozempic was selected for Cost Review by the Board on May 20, 2024.
Relevant Information:
- Presentation of findings from the drugs referred to the Stakeholder Council.
- Written comments concerning list of therapeutic alternatives (30 days).
- Comments concerning Board selection of prescription drug products for cost review.
The 60 day comment period was posted on May 23, 2024 and comments were accepted until July 22, 2024.
Comments received on Ozempic during the 60 day comment period.
The request for information for Ozempic was distributed/posted on 7/25/2024. For each prescription drug product under review, the Board may request the following information from: Manufacturer, Health Insurance Carrier, HMO, and MCO, Pharmacy Benefit Managers, and Wholesale Distributors.
Read the archived RFI notice
The draft Ozempic dossier was posted on 8/20/25 and comments were accepted through 9/4/2025.
Written Comments Received:
- August 20, 2025 Ozempic Dossier
- Exhibit 1: Pricing History_REDACTED
- Exhibit 2: RFI Submissions (NON-PUBLIC--TRADE SECRET, CONFIDENTIAL, AND PROPRIETARY)
- Exhibit 3: Ozempic Therapeutic Alternative Pricing_REDACTED
- Exhibit 4: Ozempic Therapeutic Alternative Medical Claims Data Base (MCDB) Statistics
- Exhibit 5
- Exhibit 5A: Ozempic Summary of Cost Effectiveness Analyses
- Exhibit 5B: Ozempic Summary of Comparative Effectiveness Research
- Exhibit 6
- Exhibit 6A: Written Comments (60-day COMAR 14.01.04.05C(2))
- Exhibit 6B: Written Comments (Request October 28, 2024)
The final Ozempic dossier was posted on 11/4/2025 for discussion at the 11/17/2025 Board Meeting
Written Comments Received:
- November 4, 2025 Ozempic Dossier
- Exhibit 1: Pricing History_REDACTED
- Exhibit 2: RFI Submissions (NON-PUBLIC--TRADE SECRET, CONFIDENTIAL, AND PROPRIETARY)
- Exhibit 3: Ozempic Therapeutic Alternative Pricing_REDACTED
- Exhibit 4: Ozempic Therapeutic Alternative Medical Claims Data Base (MCDB) Statistics
- Exhibit 5
- Exhibit 5A: Ozempic Summary of Cost Effectiveness Analyses
- Exhibit 5B: Ozempic Summary of Comparative Effectiveness Research
- Exhibit 6
- Exhibit 6A: Written Comments (60-day COMAR 14.01.04.05C(2))
- Exhibit 6B: Written Comments (Request October 28, 2024)
- Exhibit 6C: Written Comments (Request September 4, 2025)
The Board made a preliminary determination November 17, 2025 and this preliminary determination included:
Board Preliminary Determination
Info goes here
Info goes here
Ozempic Policy Review Process
The Policy Review, Final Action, Upper Payment Limits Authority is guided by COMAR 14.01.05.
Ozempic Policy Review Process
An informational Hearing for Ozempic took place on December 16, 2026.
Read the archived informational hearing notice - PDF - 139.38 KB
The Board discussed the preliminary Policy options at the February 23, 2026 Board meeting.
Upper Payment Limit Policy Actions
Ozempic Upper Payment Limit Policy Actions
Ozempic: Calculations and Analyses Underpinning Potential UPL Values (Posted 4/22/2026)
Staff posted a proposed version of the Ozempic: Calculations and Analyses Underpinning Potential UPL Values. Written public comments are requested. Comments were submitted in accordance with COMAR 14.01.01.05B(4) by close of business, Friday, May 1, 2026 to [email protected]
Please reference “Ozempic: Calculations and Analyses” in the subject line.
Ozempic: Calculations and Analysis Underpinning Potential UPL Values
Written Comment Packet
The Board approved to establish an Upper Payment Limit for Ozempic by adopting COMAR 14.01.07.02 as drafted and authorizing staff to submit it for review and publication in accordance with the Administrative Procedure Act at the May 18, 2026 meeting.
Non-Upper Payment Limit Policy Actions
Ozempic Non-Upper Payment Limit Policy Actions
The following Non-UPL policies were discussed at the May 18, 2026 Board meeting.
- Ozempic- Non-UPL Policies- Presentation
- Non-UPL Policy- Plan Design and PBM Reform Study and Recommendations
- Non-UPL Policy- GLP-1 Study and Recommendations
- Non-UPL Policy- Bulk Purchasing/Subscription Model
- Non-UPL Policy- Patient Navigator Program
- Non-UPL Policy- State Participation in CMMI Models
The Board Adopted a slate of NON-UPL policies for Ozempic in the following order: GLP-1 Study, Bulk/Purchasing Subscription Model, Plan Design and PBM Reform Study, and State Participation in CMMI Models: Balance and GENEROUS at the May 18, 2026 Board meeting.